W. Rathmell
Last active: 8/8/2016

Profile

Our research program is focused on the basic mechanisms, translational aspects, and clinical attributes of the renal cell carcinomas.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Haake SM, Weyandt JD, Rathmell WK (2016) Mol Cancer Res 14(7): 589-98
    › Primary publication · 27330105 (PubMed) · PMC4955752 (PubMed Central)
  2. A tale of two cancers: Complete genetic analysis of chromophobe renal cell carcinoma contrasts with clear cell renal cell carcinoma. Fahey CC, Rathmell WK (2015) Mol Cell Oncol 2(2): e979686
    › Primary publication · 27308442 (PubMed) · PMC4904899 (PubMed Central)
  3. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB (2016) Clin Cancer Res 22(22): 5605-5616
    › Primary publication · 27220961 (PubMed) · PMC5122466 (PubMed Central)
  4. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G, Cancer Genome Atlas Research Network, Artyomov MN, Schreiber R, Govindan R, Meyerson M (2016) Nat Genet 48(6): 607-16
    › Primary publication · 27158780 (PubMed) · PMC4884143 (PubMed Central)
  5. Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. Chism DD, Rathmell WK (2016) Nat Rev Nephrol 12(6): 317-8
    › Primary publication · 27108841 (PubMed) · PMC4871728 (PubMed Central)
  6. AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. Kishton RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, Macintyre AN, Goraksha-Hicks P, de Cubas AA, Liu T, Warmoes MO, Abel ED, Yeoh AE, Gershon TR, Rathmell WK, Richards KL, Locasale JW, Rathmell JC (2016) Cell Metab 23(4): 649-62
    › Primary publication · 27076078 (PubMed) · PMC4832577 (PubMed Central)
  7. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, TCGA Research Network, Noushmehr H, Iavarone A, Verhaak RG (2016) Cell 164(3): 550-63
    › Primary publication · 26824661 (PubMed) · PMC4754110 (PubMed Central)
  8. Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. Brooks SA, Khandani AH, Fielding JR, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, Rathmell WK (2016) Clin Cancer Res 22(12): 2950-9
    › Primary publication · 26787754 (PubMed) · PMC4911278 (PubMed Central)
  9. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M (2016) Urol Oncol 34(3): 122.e1-7
    › Primary publication · 26546482 (PubMed) · PMC4761468 (PubMed Central)
  10. The Molecular Taxonomy of Primary Prostate Cancer. Cancer Genome Atlas Research Network (2015) Cell 163(4): 1011-25
    › Primary publication · 26544944 (PubMed) · PMC4695400 (PubMed Central)
  11. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R (2016) N Engl J Med 374(2): 135-45
    › Primary publication · 26536169 (PubMed) · PMC4775252 (PubMed Central)
  12. Management of Indeterminate Cystic Kidney Lesions: Review of Contrast-enhanced Ultrasound as a Diagnostic Tool. Chang EH, Chong WK, Kasoji SK, Dayton PA, Rathmell WK (2016) Urology : 1-10
    › Primary publication · 26483268 (PubMed) · PMC5500195 (PubMed Central)
  13. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, TCGA Research Network, Perou CM (2015) Cell 163(2): 506-19
    › Primary publication · 26451490 (PubMed) · PMC4603750 (PubMed Central)
  14. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. Rose TL, Deal AM, Basch E, Godley PA, Rathmell WK, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI (2015) Urol Oncol 33(9): 386.e1-6
    › Primary publication · 26122712 (PubMed) · PMC5084688 (PubMed Central)
  15. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Goodson WH, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z (2015) Carcinogenesis : S254-96
    › Primary publication · 26106142 (PubMed) · PMC4480130 (PubMed Central)
  16. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Hu Z, Brooks SA, Dormoy V, Hsu CW, Hsu HY, Lin LT, Massfelder T, Rathmell WK, Xia M, Al-Mulla F, Al-Temaimi R, Amedei A, Brown DG, Prudhomme KR, Colacci A, Hamid RA, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Lowe L, Jensen L, Bisson WH, Kleinstreuer N (2015) Carcinogenesis : S184-202
    › Primary publication · 26106137 (PubMed) · PMC4492067 (PubMed Central)
  17. Genomic Classification of Cutaneous Melanoma. Cancer Genome Atlas Network (2015) Cell 161(7): 1681-96
    › Primary publication · 26091043 (PubMed) · PMC4580370 (PubMed Central)
  18. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J (2015) N Engl J Med 372(26): 2481-98
    › Primary publication · 26061751 (PubMed) · PMC4530011 (PubMed Central)
  19. Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies. Rathmell KW, Chen F, Creighton CJ (2015) Oncoscience 2(2): 81-90
    › Primary publication · 25859550 (PubMed) · PMC4381700 (PubMed Central)
  20. Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. Sendor AB, Hacker KE, Chen S, Corona AL, Sen O, Chiang DY, Snavely A, Rogers AB, Montgomery SA, Rathmell WK, McRee AJ (2015) Gastrointest Cancer : 61-71
    › Primary publication · 25844041 (PubMed) · PMC4383253 (PubMed Central)
  21. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Cancer Genome Atlas Network (2015) Nature 517(7536): 576-82
    › Primary publication · 25631445 (PubMed) · PMC4311405 (PubMed Central)
  22. Ror2 as a therapeutic target in cancer. Debebe Z, Rathmell WK (2015) Pharmacol Ther : 143-8
    › Primary publication · 25614331 (PubMed)
  23. Broad targeting of angiogenesis for cancer prevention and therapy. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith WN, Jensen LD (2015) Semin Cancer Biol : S224-S243
    › Primary publication · 25600295 (PubMed) · PMC4737670 (PubMed Central)
  24. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, Rathmell WK (2014) PLoS One 9(12): e116101
    › Primary publication · 25542006 (PubMed) · PMC4277431 (PubMed Central)
  25. Genomic investigation of etiologic heterogeneity: methodologic challenges. Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ (2014) BMC Med Res Methodol : 138
    › Primary publication · 25532962 (PubMed) · PMC4292824 (PubMed Central)
  26. Integrated genomic characterization of papillary thyroid carcinoma. Cancer Genome Atlas Research Network (2014) Cell 159(3): 676-90
    › Primary publication · 25417114 (PubMed) · PMC4243044 (PubMed Central)
  27. Renal cell carcinoma. Jonasch E, Gao J, Rathmell WK (2014) BMJ : g4797
    › Primary publication · 25385470 (PubMed) · PMC4707715 (PubMed Central)
  28. Characterization of HPV and host genome interactions in primary head and neck cancers. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R, Cancer Genome Atlas Network (2014) Proc Natl Acad Sci U S A 111(43): 15544-9
    › Primary publication · 25313082 (PubMed) · PMC4217452 (PubMed Central)
  29. The somatic genomic landscape of chromophobe renal cell carcinoma. Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, The Cancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ (2014) Cancer Cell 26(3): 319-330
    › Primary publication · 25155756 (PubMed) · PMC4160352 (PubMed Central)
  30. Comprehensive molecular profiling of lung adenocarcinoma. Cancer Genome Atlas Research Network (2014) Nature 511(7511): 543-50
    › Primary publication · 25079552 (PubMed) · PMC4231481 (PubMed Central)
  31. Comprehensive molecular characterization of gastric adenocarcinoma. Cancer Genome Atlas Research Network (2014) Nature 513(7517): 202-9
    › Primary publication · 25079317 (PubMed) · PMC4170219 (PubMed Central)
  32. PET/CT with (124)I-cG250: great potential and some open questions. Khandani AH, Rathmell WK, Wallen EM, Ivanovic M (2014) AJR Am J Roentgenol 203(2): 261-2
    › Primary publication · 25055257 (PubMed)
  33. Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84. Rathmell WK, Brooks SA, Parker JS, Nielsen ME (2014) Eur Urol 66(5): e92
    › Primary publication · 25037640 (PubMed) · PMC4294998 (PubMed Central)
  34. HIF1α and HIF2α exert distinct nutrient preferences in renal cells. Arreola A, Cowey CL, Coloff JL, Rathmell JC, Rathmell WK (2014) PLoS One 9(5): e98705
    › Primary publication · 24879016 (PubMed) · PMC4039535 (PubMed Central)
  35. Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes. Chism DD, Rathmell WK (2014) Clin Cancer Res 20(7): 1721-3
    › Primary publication · 24634386 (PubMed) · PMC4077661 (PubMed Central)
  36. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK (2014) Eur Urol 66(1): 77-84
    › Primary publication · 24613583 (PubMed) · PMC4058355 (PubMed Central)
  37. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, Moy B (2014) Oncologist 19(2): 186-92
    › Primary publication · 24449096 (PubMed) · PMC3926786 (PubMed Central)
  38. Racial difference in histologic subtype of renal cell carcinoma. Olshan AF, Kuo TM, Meyer AM, Nielsen ME, Purdue MP, Rathmell WK (2013) Cancer Med 2(5): 744-9
    › Primary publication · 24403240 (PubMed) · PMC3892806 (PubMed Central)
  39. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb JD, Rathmell WK, Davis IJ (2014) Genome Res 24(2): 241-50
    › Primary publication · 24158655 (PubMed) · PMC3912414 (PubMed Central)
  40. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, Stadler WM (2013) Cancer Med 2(4): 545-52
    › Primary publication · 24156027 (PubMed) · PMC3799289 (PubMed Central)
  41. Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response. Desimone MC, Rathmell WK, Threadgill DW (2013) J Natl Cancer Inst 105(18): 1355-64
    › Primary publication · 23990666 (PubMed) · PMC3776265 (PubMed Central)
  42. The molecular biology of renal cell carcinoma. Keefe SM, Nathanson KL, Rathmell WK (2013) Semin Oncol 40(4): 421-8
    › Primary publication · 23972705 (PubMed)
  43. Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. Rasmussen NR, Wright TM, Brooks SA, Hacker KE, Debebe Z, Sendor AB, Walker MP, Major MB, Green J, Wahl GM, Rathmell WK (2013) J Biol Chem 288(36): 26301-10
    › Primary publication · 23893409 (PubMed) · PMC3764835 (PubMed Central)
  44. Ethical challenges: managing oncology drug shortages. Valgus J, Singer EA, Berry SR, Rathmell WK (2013) J Oncol Pract 9(2): e21-3
    › Primary publication · 23814521 (PubMed) · PMC3595447 (PubMed Central)
  45. Physician and stakeholder perceptions of conflict of interest policies in oncology. Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, Rathmell WK (2013) J Clin Oncol 31(13): 1677-82
    › Primary publication · 23530092 (PubMed) · PMC4525129 (PubMed Central)
  46. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O (2013) Cell Metab 17(3): 372-85
    › Primary publication · 23473032 (PubMed) · PMC4003458 (PubMed Central)
  47. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database--UNC GOLD. Gallagher SA, Smith AB, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, Rathmell WK, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, Barocas DA, Pruthi RS, Nielsen ME, Milowsky MI (2014) Urol Oncol 32(1): 32.e1-9
    › Primary publication · 23434424 (PubMed) · PMC4058502 (PubMed Central)
  48. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J (2013) Lancet Oncol 14(2): 159-167
    › Primary publication · 23333114 (PubMed) · PMC4674067 (PubMed Central)
  49. Kidney cancer. Linehan WM, Rathmell WK (2012) Urol Oncol 30(6): 948-51
    › Primary publication · 23218074 (PubMed) · PMC4419144 (PubMed Central)
  50. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE (2012) BJU Int 110(11 Pt B): E721-6
    › Primary publication · 23016517 (PubMed)
  51. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Khandani AH, Cowey CL, Moore DT, Gohil H, Rathmell WK (2012) Nucl Med Commun 33(9): 967-73
    › Primary publication · 22714005 (PubMed)
  52. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Khandani AH, Rathmell WK (2012) Semin Nucl Med 42(4): 221-30
    › Primary publication · 22681671 (PubMed)
  53. State of the science: an update on renal cell carcinoma. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK (2012) Mol Cancer Res 10(7): 859-80
    › Primary publication · 22638109 (PubMed) · PMC3399969 (PubMed Central)
  54. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. Gamper AM, Qiao X, Kim J, Zhang L, DeSimone MC, Rathmell WK, Wan Y (2012) Mol Cell 45(2): 233-43
    › Primary publication · 22284679 (PubMed) · PMC3982234 (PubMed Central)
  55. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK (2012) Eur Urol 61(2): 258-68
    › Primary publication · 22030119 (PubMed) · PMC3244546 (PubMed Central)
  56. Carcinoma in a cadaveric transplant kidney. Manvar AM, Rathmell WK, Ferguson J, Pruthi RS, Nielsen ME, Wallen EM, Nolan N, Raynor MC (2012) Urology 79(4): 758-60
    › Primary publication · 22014593 (PubMed)
  57. Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Teng BL, Hacker KE, Chen S, Means AR, Rathmell WK (2011) Mol Oncol 5(5): 465-74
    › Primary publication · 21764651 (PubMed) · PMC3194764 (PubMed Central)
  58. Basic research in kidney cancer. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A (2011) Eur Urol 60(4): 622-33
    › Primary publication · 21741760 (PubMed) · PMC4877128 (PubMed Central)
  59. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. Rasmussen N, Rathmell WK (2011) Curr Clin Pharmacol 6(3): 199-206
    › Primary publication · 21470103 (PubMed)
  60. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ (2013) Urol Oncol 31(1): 82-6
    › Primary publication · 21396844 (PubMed)
  61. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, Rathmell WK (2010) Genes Cancer 1(2): 152-163
    › Primary publication · 20871783 (PubMed) · PMC2943630 (PubMed Central)
  62. Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Cowey CL, Rathmell WK (2008) Expert Opin Drug Discov 3(3): 311-327
    › Primary publication · 20648240 (PubMed) · PMC2906134 (PubMed Central)
  63. Emerging molecular classification in renal cell carcinoma: implications for drug development. Hacker KE, Rathmell WK (2010) Target Oncol 5(2): 75-84
    › Primary publication · 20645016 (PubMed) · PMC3392717 (PubMed Central)
  64. Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue. Benders AA, Tang W, Middeldorp JM, Greijer AE, Thorne LB, Funkhouser WK, Rathmell WK, Gulley ML (2009) Head Neck Pathol 3(4): 276-82
    › Primary publication · 20596845 (PubMed) · PMC2811562 (PubMed Central)
  65. Renal cell carcinoma: where will the state-of-the-art lead us? Brannon AR, Rathmell WK (2010) Curr Oncol Rep 12(3): 193-201
    › Primary publication · 20425079 (PubMed) · PMC2906141 (PubMed Central)
  66. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, Ganesan S, Levine AJ, Rathmell WK, Bhanot GV (2010) BMC Syst Biol : 51
    › Primary publication · 20420713 (PubMed) · PMC2876063 (PubMed Central)
  67. VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Chen S, Sanford CA, Sun J, Choi V, Van Dyke T, Samulski RJ, Rathmell WK (2010) Angiogenesis 13(1): 59-69
    › Primary publication · 20221685 (PubMed) · PMC2872996 (PubMed Central)
  68. Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma. Wright TM, Rathmell WK (2010) J Biol Chem 285(17): 12916-24
    › Primary publication · 20185829 (PubMed) · PMC2857057 (PubMed Central)
  69. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK (2010) J Clin Oncol 28(9): 1502-7
    › Primary publication · 20159822 (PubMed) · PMC4525128 (PubMed Central)
  70. Recent updates in renal cell carcinoma. Rathmell WK, Godley PA (2010) Curr Opin Oncol 22(3): 250-6
    › Primary publication · 20154618 (PubMed) · PMC2906148 (PubMed Central)
  71. Neoadjuvant treatment of renal cell carcinoma. Rathmell WK, Pruthi R, Wallen E (2010) Urol Oncol 28(1): 69-73
    › Primary publication · 20123351 (PubMed)
  72. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, Whang Y, Fielding J, Schultz H, Grigson G, Smith A, Kim W (2010) BJU Int 106(3): 349-54
    › Primary publication · 20089114 (PubMed)
  73. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA (2011) Urol Oncol 29(6): 608-13
    › Primary publication · 20022268 (PubMed)
  74. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Cowey CL, Fielding JR, Rathmell WK (2010) Urology 75(5): 1108-13.e1
    › Primary publication · 19931124 (PubMed)
  75. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Kurpad R, Kim W, Rathmell WK, Godley P, Whang Y, Fielding J, Smith L, Pettiford A, Schultz H, Nielsen M, Wallen EM, Pruthi RS (2011) Urol Oncol 29(4): 378-82
    › Primary publication · 19576797 (PubMed)
  76. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, Edwards L, Nusse R, Rathmell WK (2009) Oncogene 28(27): 2513-23
    › Primary publication · 19448672 (PubMed) · PMC2771692 (PubMed Central)
  77. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Lee CM, Hickey MM, Sanford CA, McGuire CG, Cowey CL, Simon MC, Rathmell WK (2009) Oncogene 28(14): 1694-705
    › Primary publication · 19252526 (PubMed) · PMC2667565 (PubMed Central)
  78. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Cowey CL, Rathmell WK (2009) Curr Oncol Rep 11(2): 94-101
    › Primary publication · 19216840 (PubMed) · PMC2873025 (PubMed Central)
  79. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL (2008) Cancer Cell 14(6): 435-46
    › Primary publication · 19061835 (PubMed) · PMC2621440 (PubMed Central)
  80. VHL type 2B mutations retain VBC complex form and function. Hacker KE, Lee CM, Rathmell WK (2008) PLoS One 3(11): e3801
    › Primary publication · 19030229 (PubMed) · PMC2583047 (PubMed Central)
  81. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK (2008) Urology 72(4): 864-8
    › Primary publication · 18684493 (PubMed)
  82. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. Rathmell WK, Monk JP (2008) Urology 72(3): 659-63
    › Primary publication · 18649931 (PubMed)
  83. Renal cell carcinoma. Rini BI, Rathmell WK, Godley P (2008) Curr Opin Oncol 20(3): 300-6
    › Primary publication · 18391630 (PubMed)
  84. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Rathmell WK, Chen S (2008) Expert Rev Anticancer Ther 8(1): 63-73
    › Primary publication · 18095884 (PubMed) · PMC2873028 (PubMed Central)
  85. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC (2007) J Clin Invest 117(12): 3879-89
    › Primary publication · 17992257 (PubMed) · PMC2066197 (PubMed Central)
  86. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ (2007) J Clin Oncol 25(22): 3288-95
    › Primary publication · 17664476 (PubMed)
  87. Renal cell carcinoma. Rathmell WK, Martz CA, Rini BI (2007) Curr Opin Oncol 19(3): 234-40
    › Primary publication · 17414642 (PubMed)
  88. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Rini BI, Rathmell WK (2007) Clin Cancer Res 13(2 Pt 2): 741s-746s
    › Primary publication · 17255303 (PubMed)
  89. Renal cell carcinoma. Rini BI, Campbell SC, Rathmell WK (2006) Curr Opin Oncol 18(3): 289-96
    › Primary publication · 16552243 (PubMed)
  90. Molecularly targeted therapy in renal cell carcinoma. Rathmell WK, Wright TM, Rini BI (2005) Expert Rev Anticancer Ther 5(6): 1031-40
    › Primary publication · 16336094 (PubMed)
  91. VHL: oxygen sensing and vasculogenesis. Rathmell WK, Simon MC (2005) J Thromb Haemost 3(12): 2627-32
    › Primary publication · 15975138 (PubMed)
  92. Renal cell carcinoma. Rathmell WK, Godley PA, Rini BI (2005) Curr Opin Oncol 17(3): 261-7
    › Primary publication · 15818172 (PubMed)
  93. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC (2004) Cancer Res 64(23): 8595-603
    › Primary publication · 15574766 (PubMed)
  94. Renal cell carcinoma. Rathmell WK, Godley PA (2004) Curr Opin Oncol 16(3): 247-52
    › Primary publication · 15069321 (PubMed)
  95. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. Rathmell WK, Malkowicz SB, Holroyde C, Luginbuhl W, Vaughn DJ (2004) Am J Clin Oncol 27(2): 109-12
    › Primary publication · 15057147 (PubMed)
  96. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Rathmell WK, Acs G, Simon MC, Vaughn DJ (2004) Anticancer Res 24(1): 167-9
    › Primary publication · 15015593 (PubMed)
  97. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC (2003) Cancer Cell 3(1): 75-88
    › Primary publication · 12559177 (PubMed) · PMC4120823 (PubMed Central)
  98. The wheat-grain proteome as a basis for more efficient cultivar identification. Skylas DJ, Copeland L, Rathmell WG, Wrigley CW (2001) Proteomics 1(12): 1542-6
    › Primary publication · 11747214 (PubMed)
  99. Yersinia pseudotuberculosis bacteremia and splenic abscess in a patient with non-insulin-dependent diabetes mellitus. Rathmell WK, Arguin P, Chan S, Yu A (1999) West J Med 170(2): 110-2
    › Primary publication · 10063398 (PubMed) · PMC1305451 (PubMed Central)
  100. Failure of hairpin-ended and nicked DNA To activate DNA-dependent protein kinase: implications for V(D)J recombination. Smider V, Rathmell WK, Brown G, Lewis S, Chu G (1998) Mol Cell Biol 18(11): 6853-8
    › Primary publication · 9774698 (PubMed) · PMC109268 (PubMed Central)
  101. DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. Rathmell WK, Kaufmann WK, Hurt JC, Byrd LL, Chu G (1997) Cancer Res 57(1): 68-74
    › Primary publication · 8988043 (PubMed)
  102. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. Errami A, Smider V, Rathmell WK, He DM, Hendrickson EA, Zdzienicka MZ, Chu G (1996) Mol Cell Biol 16(4): 1519-26
    › Primary publication · 8657125 (PubMed) · PMC231136 (PubMed Central)
  103. Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. Rathmell WK, Chu G (1994) Proc Natl Acad Sci U S A 91(16): 7623-7
    › Primary publication · 8052631 (PubMed) · PMC44454 (PubMed Central)
  104. Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. Smider V, Rathmell WK, Lieber MR, Chu G (1994) Science 266(5183): 288-91
    › Primary publication · 7939667 (PubMed)
  105. A DNA end-binding factor involved in double-strand break repair and V(D)J recombination. Rathmell WK, Chu G (1994) Mol Cell Biol 14(7): 4741-8
    › Primary publication · 7516471 (PubMed) · PMC358847 (PubMed Central)
  106. Early heart development in the chick embryo: effects of isotretinoin on cell proliferation, alpha-actin synthesis, and development of contractions. Wiens DJ, Mann TK, Fedderson DE, Rathmell WK, Franck BH (1992) Differentiation 51(2): 105-12
    › Primary publication · 1473624 (PubMed)